EMEA-002270-PIP04-20
Key facts
Active substance |
Marzeptacog alfa (activated)
|
Therapeutic area |
Haematology-Hemostaseology
|
Decision number |
P/0482/2021
|
PIP number |
EMEA-002270-PIP04-20
|
Pharmaceutical form(s) |
Powder for solution for injection
|
Condition(s) / indication(s) |
Treatment of Haemophilia B
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Catalyst Biosciences, Inc.
Email: cdemocko@catbio.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|